Thursday, June 22, 2017 9:15:05 PM
Recent BPTH News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:00:34 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/08/2024 10:11:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 12:10:34 PM
- Bio-Path Holdings Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/08/2024 12:00:00 PM
- U.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices Dip • IH Market News • 03/08/2024 11:22:25 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:21:27 PM
- Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 • GlobeNewswire Inc. • 03/01/2024 12:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/29/2024 11:00:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 12:01:09 PM
- Bio-Path Holdings Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 09:39:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:10:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:20:23 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:51:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/17/2024 09:52:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:10:09 PM
- Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients • GlobeNewswire Inc. • 01/10/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/04/2024 10:18:53 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/22/2023 09:06:16 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 09:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:05:23 PM
- Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia • GlobeNewswire Inc. • 12/14/2023 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/08/2023 09:05:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:05:35 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM